Voloridge Investment Management
ERNA icon

Voloridge Investment Management’s Eterna Therapeutics ERNA Stock Holding History

Voloridge Investment Management’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6
Closed -$453K – 1635
2021
Q3 		$453K Buy
+6
New +$518K ﹤0.01% 1481

Other funds holding ERNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Voloridge Investment Management's ERNA Position: Q4 2021 in Review

Voloridge Investment Management sold out of Eterna Therapeutics (ERNA) in Q4 2021, closing a stake of 6 shares — an estimated $453K sold.

Voloridge Investment Management first reported a position in ERNA in Q3 2021 and held it in 1 quarter. The position peaked at $453K in Q3 2021. 47 funds tracked by Wall St. Rank hold ERNA as of Q4 2021.

  • Voloridge Investment Management reported no remaining Eterna Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Voloridge Investment Management sold 6 Eterna Therapeutics shares in Q4 2021, an estimated $453K.
  • Voloridge Investment Management first reported a position in Eterna Therapeutics in Q3 2021 and held it in 1 quarter.
  • Voloridge Investment Management's Eterna Therapeutics position peaked at $453K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2021.

Based on Voloridge Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.